Survodutide heart-safety trial finishes its main measurement period
Survodutide's 5,531-person heart-safety study has finished collecting its main results, but no data are public yet, so the drug's cardiovascular risk is still unknown.
The cardiovascular safety trial for survodutide, an investigational drug for people with overweight or obesity, has finished its main measurement period. It is the first of the current wave of heart-safety trials for newer obesity drugs to reach that stage [1].
The trial is registered on ClinicalTrials.gov as NCT06077864 under the name SYNCHRONIZE-CVOT. The registry describes it as a study to test the effect of survodutide, also called BI 456906, on cardiovascular safety in people with overweight or obesity [1]. It enrolled 5,531 participants [1].
The registry lists the study's primary completion date — the point at which the last participant is measured for the trial's main outcome — as June 1, 2026 [1]. Reaching that date means the data have been gathered, not that they have been analyzed, released or reviewed by regulators.
As of September 14, 2026, results from the trial had not been published [1]. The central question the study was built to answer — whether survodutide affects cardiovascular outcomes in this group of patients — has not been answered in public.
The trial record identifies the study drug as survodutide, or BI 456906 [1]. That is a different molecule from semaglutide, sold as Ozempic, Wegovy and Rybelsus, and from tirzepatide, sold as Mounjaro and Zepbound. Heart-safety findings from this trial would apply to survodutide, not to those approved products.
Why it matters for patients
Heart safety is a separate question from weight loss. SYNCHRONIZE-CVOT was set up specifically to measure cardiovascular safety in people with overweight or obesity [1], which is the kind of information regulators and doctors weigh when deciding how a weight-loss drug fits alongside other options.
For now, the completed measurement period gives patients no usable information. Nothing about survodutide's effect on heart risk — good, bad or neutral — is known from this trial until results are published and reviewed. Anyone taking an approved GLP-1 medicine for weight or diabetes does not get an answer about their own drug from this study.
Trials of this type are watched while they run by an independent data monitoring committee, a group of outside scientists that can recommend stopping a study if it is not effective, is harming participants, or is unlikely to serve its scientific purpose [1]. No such action has been reported for SYNCHRONIZE-CVOT.
It is also worth being precise about the word "completed." The end of a measurement period is not FDA review, not an approval decision and not a published result.
What happens next
Under ClinicalTrials.gov reporting rules, results are generally due within about one year of the primary completion date. A sponsor seeking FDA approval of a new drug can certify a delay of up to two years after that certification, and can request an extension for good cause [1]. Whether a certification or extension request applies to this trial has not been disclosed.
Whether the sponsor plans to seek FDA approval for survodutide, and on what timeline, has not been reported.
Other cardiovascular outcomes trials for experimental obesity drugs are still running. Their schedules and completion dates have not been reported here, and no date has been announced for the release of the SYNCHRONIZE-CVOT results.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.